ERBB2 and neoplasm: A better understanding of the multiples barriers seen in solid tumors and a combination of various safety strategies will drive advances in HER2 CAR engineering and in clinical trial design to control and/or minimize potential “off tumor, on target” toxicity of HER2 CAR therapy.